ATE167629T1 - Arzneimittel mit verzögerter freigabe - Google Patents

Arzneimittel mit verzögerter freigabe

Info

Publication number
ATE167629T1
ATE167629T1 AT94200469T AT94200469T ATE167629T1 AT E167629 T1 ATE167629 T1 AT E167629T1 AT 94200469 T AT94200469 T AT 94200469T AT 94200469 T AT94200469 T AT 94200469T AT E167629 T1 ATE167629 T1 AT E167629T1
Authority
AT
Austria
Prior art keywords
delayed release
medicinal products
active ingredient
release medicinal
core element
Prior art date
Application number
AT94200469T
Other languages
English (en)
Inventor
Angelo Mario Morella
Mark Christopher Fisher
Original Assignee
Faulding F H & Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faulding F H & Co Ltd filed Critical Faulding F H & Co Ltd
Application granted granted Critical
Publication of ATE167629T1 publication Critical patent/ATE167629T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT94200469T 1989-01-06 1990-01-05 Arzneimittel mit verzögerter freigabe ATE167629T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPJ219289 1989-01-06

Publications (1)

Publication Number Publication Date
ATE167629T1 true ATE167629T1 (de) 1998-07-15

Family

ID=3773627

Family Applications (2)

Application Number Title Priority Date Filing Date
AT90300130T ATE133862T1 (de) 1989-01-06 1990-01-05 Arzneimittel mit verzögerter freigabe
AT94200469T ATE167629T1 (de) 1989-01-06 1990-01-05 Arzneimittel mit verzögerter freigabe

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT90300130T ATE133862T1 (de) 1989-01-06 1990-01-05 Arzneimittel mit verzögerter freigabe

Country Status (10)

Country Link
EP (2) EP0377518B1 (de)
JP (1) JP2937376B2 (de)
AT (2) ATE133862T1 (de)
CA (1) CA2007181C (de)
DE (2) DE69032445T2 (de)
DK (2) DK0609961T3 (de)
ES (2) ES2120562T3 (de)
GR (1) GR3019201T3 (de)
HK (1) HK154296A (de)
NZ (1) NZ232029A (de)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2288117A (en) * 1994-03-01 1995-10-11 Euro Celtique Sa Sustained release morphine
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
GB2281204A (en) * 1993-07-27 1995-03-01 Euro Celtique Sa Sustained release morphine compositions
US5968551A (en) 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5681585A (en) 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
GB2284760B (en) * 1993-11-23 1998-06-24 Euro Celtique Sa A method of preparing pharmaceutical compositions by melt pelletisation
US5286493A (en) * 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US7070806B2 (en) 1992-01-27 2006-07-04 Purdue Pharma Lp Controlled release formulations coated with aqueous dispersions of acrylic polymers
SE9202250D0 (sv) * 1992-07-29 1992-07-29 Gacell Lab Ab Controlled release morphine preparation
ZA937382B (en) * 1992-10-06 1994-04-29 Warner Lambert Co Novel composition for peroral therapy of cognitionimpairment and a process therefor
SE9301057L (sv) * 1993-03-30 1994-10-01 Pharmacia Ab Beredning med kontrollerad frisättning
NZ260408A (en) 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US7740881B1 (en) 1993-07-01 2010-06-22 Purdue Pharma Lp Method of treating humans with opioid formulations having extended controlled release
IL109944A (en) 1993-07-01 1998-12-06 Euro Celtique Sa Sustained release dosage unit forms containing morphine and a method of preparing these sustained release dosage unit forms
EP0711166A1 (de) * 1993-07-22 1996-05-15 Warner-Lambert Company Tacrin-arzneistoffabgabesysteme mit kontrollierter freisetzung und herstellungsverfahren
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
EP1442745A1 (de) * 1993-10-07 2004-08-04 Euro-Celtique Oral anzuwendende opioidhaltige Zusammensetzungen mit verlängerter Wirkung
US5891471A (en) 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
KR100354702B1 (ko) * 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
US5843480A (en) 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
AT403988B (de) * 1994-05-18 1998-07-27 Lannacher Heilmittel Festes orales retardpräparat
US5460826A (en) * 1994-06-27 1995-10-24 Alza Corporation Morphine therapy
US6491945B1 (en) * 1994-09-16 2002-12-10 Alza Corporation Hydrocodone therapy
GB9422154D0 (en) 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US5744164A (en) * 1994-12-16 1998-04-28 Nestec S.A. Sustained release microparticulate caffeine formulation
US5834024A (en) 1995-01-05 1998-11-10 Fh Faulding & Co. Limited Controlled absorption diltiazem pharmaceutical formulation
GB9519363D0 (en) 1995-09-22 1995-11-22 Euro Celtique Sa Pharmaceutical formulation
US6245351B1 (en) * 1996-03-07 2001-06-12 Takeda Chemical Industries, Ltd. Controlled-release composition
FR2752732B1 (fr) * 1996-08-28 1998-11-20 Pf Medicament Forme galenique a liberation prolongee de milnacipran
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
EP0946151B1 (de) * 1996-11-25 2006-05-10 Alza Corporation Dosisform mit ansteigender dosisfreisetzung
US5948787A (en) * 1997-02-28 1999-09-07 Alza Corporation Compositions containing opiate analgesics
US6306438B1 (en) 1997-07-02 2001-10-23 Euro-Celtique, S.A. Stabilized sustained release tramadol formulations
US6066339A (en) * 1997-10-17 2000-05-23 Elan Corporation, Plc Oral morphine multiparticulate formulation
TR200001942T2 (tr) * 1997-12-22 2000-11-21 Euro-Celtique, S.A. Opioid agonist/antagonist kombinasyonlar
WO1999047128A1 (en) * 1998-03-19 1999-09-23 Bristol-Myers Squibb Company Biphasic controlled release delivery system for high solubility pharmaceuticals and method
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
DE19918325A1 (de) 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
FR2794646B1 (fr) * 1999-06-09 2001-09-21 Ethypharm Lab Prod Ethiques Microgranules de sulfate de morphine, procede de preparation et composition les contenant
BR0013720A (pt) * 1999-09-02 2002-07-23 Nostrum Pharmaceuticals Inc Formulação em pelota de liberação controlada
JP2003509439A (ja) * 1999-09-14 2003-03-11 スミスクライン・ビーチャム・コーポレイション 水性コーティングされたビーズレットの製法
EP2295043A1 (de) 1999-10-29 2011-03-16 Euro-Celtique S.A. Hydrocodon-Formulierungen mit gesteuerter Freisetzung
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
US6242003B1 (en) 2000-04-13 2001-06-05 Novartis Ag Organic compounds
JP2002003366A (ja) * 2000-06-23 2002-01-09 Freunt Ind Co Ltd 固形薬剤用水系コーティング剤組成物
FR2811571B1 (fr) 2000-07-11 2002-10-11 Flamel Tech Sa Composition pharmaceutique orale, permettant la liberation controlee et l'absorption prolongee d'un principe actif
US8858961B2 (en) 2000-07-14 2014-10-14 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
IT1318625B1 (it) 2000-07-14 2003-08-27 Roberto Valducci Formulazioni farmaceutiche solide orali a rilascio multifasicoph-dipendente.
EP1365811A2 (de) 2000-07-14 2003-12-03 Allergan, Inc. Zusammensetzungen enthaltend alpha-2-adrenergische agonisten
CA2416169C (en) 2000-07-14 2008-09-23 Allergan, Inc. Compositions containing therapeutically active components having enhanced solubility
AU2002227383B2 (en) 2000-10-30 2004-07-08 Euro-Celtique S.A. Controlled release hydrocodone formulations
US20060127474A1 (en) 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
UA81224C2 (uk) 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
US6524618B1 (en) 2001-06-12 2003-02-25 Vijai Kumar Directly compressible extended-release matrix formulation for metformin hydrochloride
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
JP4732696B2 (ja) 2002-04-09 2011-07-27 フラメル・テクノロジー 活性成分の改変された放出のための、マイクロカプセルの水性懸濁液形態での経口医薬品製剤
TW200404544A (en) * 2002-06-17 2004-04-01 Kowa Co Controlled release pharmaceutical composition
KR20060092255A (ko) 2003-09-26 2006-08-22 알자 코포레이션 고도의 약물적재를 제공하는 약물코팅제 및 그의 제조방법
EP1680098A4 (de) * 2003-11-04 2012-06-13 Supernus Pharmaceuticals Inc Verzögerte freisetzung von positiv geladenen pharmakologisch wirksamen molekülen aus einer polymer-haltigen matrix mit polarisierten sauerstoffatomen
WO2006124890A1 (en) * 2005-05-13 2006-11-23 Alpharma, Inc. Morphine sulphate formulations
WO2006124898A1 (en) * 2005-05-13 2006-11-23 Alpharma, Inc. Morphine sulfate formulations
AU2006275476A1 (en) * 2005-08-01 2007-02-08 Alpharma Inc. Alcohol resistant pharmaceutical formulations
US11311490B2 (en) 2005-08-10 2022-04-26 Add Advanced Drug Delivery Technologies Ltd. Oral preparation with controlled release
US20070264346A1 (en) * 2006-02-16 2007-11-15 Flamel Technologies Multimicroparticulate pharmaceutical forms for oral administration
CN104825397A (zh) * 2006-04-03 2015-08-12 伊萨·奥迪迪 含有机溶胶涂层的受控释放递送物件
US9023400B2 (en) 2006-05-24 2015-05-05 Flamel Technologies Prolonged-release multimicroparticulate oral pharmaceutical form
FR2901478B1 (fr) * 2006-05-24 2015-06-05 Flamel Tech Sa Forme pharmaceutique orale multimicroparticulaire a liberation prolongee
FR2946533A1 (fr) 2009-06-12 2010-12-17 Ethypharm Sa Reduction des fluctuations plasmatiques d'opioides.
FR2951378B1 (fr) * 2009-10-16 2012-06-01 Flamel Tech Sa Forme pharmaceutique orale solide anti-mesusage et dotee d'un profil specifique de liberation modifiee
RU2596787C2 (ru) 2010-07-09 2016-09-10 БиЭйчВи ФАРМА, ИНК. Комбинированная система доставки с немедленным/замедленным высвобождением для лекарственных средств с коротким периодом полувыведения, в том числе для ремоглифлозина
US20120251588A1 (en) * 2011-03-30 2012-10-04 Miyuki Fukasawa Coating Composition, Solid Preparation Coated Therewith, and Method for Preparing Solid Preparation
EP2606879A1 (de) 2011-12-21 2013-06-26 Hexal AG Multipartikuläre Tablette enthaltend ein Opioid
CA2910865C (en) 2014-07-15 2016-11-29 Isa Odidi Compositions and methods for reducing overdose
US20170182070A1 (en) * 2014-10-08 2017-06-29 Mayne Pharma International Pty Ltd. Controlled Release Doxycycline
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10835499B2 (en) 2015-12-30 2020-11-17 Corium, Inc. Systems and methods for long term transdermal administration
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CN109922796B (zh) 2016-06-23 2023-04-07 考里安有限责任公司 具有亲水和疏水域的粘合剂基质和治疗剂
JP7071330B2 (ja) * 2016-07-27 2022-05-18 コリウム, インコーポレイテッド 炭酸水素ナトリウムのin situ変換で促進されたアミン薬物の経皮送達
US10765635B2 (en) 2018-02-06 2020-09-08 Nano Pharmaceutical Laboratories Llc Multiparticulate including pharmaceutical or probiotic active ingredients for delivery via a shelf stable liquid dosage form

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8414220D0 (en) * 1984-06-04 1984-07-11 Sterwin Ag Medicaments in unit dose form
GB8514665D0 (en) * 1985-06-11 1985-07-10 Eroceltique Sa Oral pharmaceutical composition
SE460947B (sv) * 1986-08-26 1989-12-11 Lejus Medical Ab En multiple-unit-dos komposition av l-dopa
EP0327295A3 (de) * 1988-02-01 1989-09-06 F.H. FAULDING & CO. LTD. Tetracyclin-Dosisform

Also Published As

Publication number Publication date
ES2120562T3 (es) 1998-11-01
ATE133862T1 (de) 1996-02-15
GR3019201T3 (en) 1996-06-30
DE69025208T2 (de) 1996-06-13
JP2937376B2 (ja) 1999-08-23
NZ232029A (en) 1992-04-28
CA2007181A1 (en) 1990-07-06
EP0377518A2 (de) 1990-07-11
AU4773290A (en) 1990-07-12
DK0609961T3 (da) 1999-04-06
DE69032445D1 (de) 1998-07-30
CA2007181C (en) 1998-11-24
EP0377518B1 (de) 1996-02-07
EP0609961B1 (de) 1998-06-24
EP0377518A3 (en) 1990-10-24
DE69025208D1 (de) 1996-03-21
JPH032114A (ja) 1991-01-08
EP0609961A1 (de) 1994-08-10
HK154296A (en) 1996-08-16
ES2085886T3 (es) 1996-06-16
DK0377518T3 (da) 1996-06-24
DE69032445T2 (de) 1999-02-18
AU617573B2 (en) 1991-11-28

Similar Documents

Publication Publication Date Title
ATE133862T1 (de) Arzneimittel mit verzögerter freigabe
ATE154239T1 (de) Sphäroidische arzneimittelformulierung
ES2062417T3 (es) Composiciones farmaceuticas de cimetidina.
EP0377517A3 (de) Theophyllin-Dosisform
ES2172239T3 (es) Sistema osmotico de liberacion de farmacos.
ATE74519T1 (de) Waessrige loesung von fettloeslichen wirkstoffen.
DE3773468D1 (de) Hydromorphon-zusammensetzung mit gesteuerter wirkstofffreisetzung.
DE69435295D1 (de) Tramadolhaltiges Arzneimittel mit gesteuerter Wirkstoffabgabe
FR2683146B1 (fr) Compositions pharmaceutiques a liberation reglee de la substance medicamenteuse.
IL111519A0 (en) Sustained release tablets having an insoluble active ingredient therein and methods for the preparation thereof
HUT60466A (en) Process for producing amino acid derivatives and pharmaceutical compositions comprising such active ingredient
ATE151285T1 (de) Orale arzneimittel mit kolonspezifischer freisetzung
ATE198152T1 (de) Oral anzuwendende arzneizubereitung mit verzögerter wirkstoffabgabe
DK555089D0 (da) Farmaceutiske praeparater indeholdende n-(3,4-dimethoxycinnamoyl)anthranilsyre
CA2190303A1 (en) Pharmaceutical composition, method and device for preventing or treating dry eye or disease caused therefrom
IT8820073A0 (it) Formulazioni farmaceutiche acquose di piroxicam e procedimento per laloro preparazione.
DE69108022D1 (de) Arzneimittel.
IL90056A (en) Topical pharmaceutical compositions containing 4-quinoline carboxylic acid derivatives
CA2214531A1 (en) Treatment of cytokine growth factor caused disorders
ITMI911880A1 (it) Metodo per la preparazione di forme farmaceutiche orali a rilascio prolungato contenenti sostanze attive a solubilita' dipendente dal valore di ph.
FR2681863B1 (fr) Solution de sparfloxacine sa preparation et sel la constituant.
NO913644D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive aminosyrederivater.
IT1255237B (it) Composizione farmaceuticaidrofila ad attivita' antiinfiammatoria
ITBO920455A1 (it) Procedimento per preparare forme farmaceutiche a rilascio controllato ritardato del principio attivo e le forme farmaceutiche cosi' ottenute.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEFA Change of the company name
EELA Cancelled due to lapse of time